Covalon Technologies (OTCMKTS:CVALF) Announces Earnings Results, Beats Expectations By $0.06 EPS

Covalon Technologies (OTCMKTS:CVALF) posted its earnings results on Friday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.06, Zacks reports. Covalon Technologies had a net margin of 8.58% and a return on equity of 12.33%.

Covalon Technologies Stock Performance

Shares of OTCMKTS CVALF traded up $0.04 during mid-day trading on Friday, reaching $2.25. 33,532 shares of the company traded hands, compared to its average volume of 11,841. The company’s fifty day moving average is $2.23 and its two-hundred day moving average is $2.32. Covalon Technologies has a fifty-two week low of $0.74 and a fifty-two week high of $3.08. The stock has a market cap of $61.65 million, a PE ratio of 32.15 and a beta of -0.29.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.